Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Ipamorelin Half-Life vs Other Growth Hormone Secretagogues

Ipamorelin ~2 hours 30–45 min 3–4 hours 2–3x daily High (GHS-R1a only, no cortisol/prolactin) GHRP-2 ~30 min 20–30 min 2–3 hours Moderate (some cortisol elevation at high doses) GHRP-6 Low (significant cortisol, prolactin, ghrelin effects) CJC-1295 (no DAC) 30

This comparison does not assign a generated winner or score.

  • Ipamorelin
  • ~2 hours
  • 30–45 min
  • 3–4 hours
  • 2–3x daily
  • High (GHS-R1a only, no cortisol/prolactin)
  • GHRP-2
  • ~30 min
  • 20–30 min
  • 2–3 hours
  • Moderate (some cortisol elevation at high doses)
  • GHRP-6
  • Low (significant cortisol, prolactin, ghrelin effects)
  • CJC-1295 (no DAC)
  • 30–60 min
  • High (GHRH receptor specific)
  • CJC-1295 DAC
  • 6–8 days
  • 2–4 hours
  • Continuous (steady-state)
  • 1x weekly
  • High (GHRH receptor, but blunts natural pulsatility)
  • MK-677 (oral)
  • 4–6 hours
  • 60–90 min
  • 24+ hours (oral bioavailability)
  • 1x daily
  • Moderate (some appetite stimulation via ghrelin pathway)
  • What's the half-life of ipamorelin positions it in the middle tier. Long enough to avoid the rapid degradation of unmodified GHRP variants but short enough to preserve dose independence and natural GH rhythm. The comparison clarifies why many protocols pair ipamorelin with CJC-1295 (no DAC): the former provides pulsatile GH release with predictable clearance, while the latter amplifies each pulse without extending background suppression. Together, they mimic physiological GH secretion patterns more closely than either compound alone.